Lundbeck
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Denmark · 5K - 10K Employees
View Company Info for Free
Overview
Headquarters
Ottiliavej 9, Valby, Capital Region, 250...Phone Number
+45 36301311Website
www.lundbeck.comRevenue
$3.1 BillionStock Symbol
HLBBFIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
1
1
1
About Lundbeck
Lundbeck, founded in 1915 and headquartered in Valby Denmark, is an international pharmaceutical company that researches, manufactures, and sells drugs for the treatment of psychiatric and neurological disorders.Explore more
Lundbeck Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Lundbeck your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Lundbeck has recently received funding, and reach out quickly before it becomes old news!
Lundbeck, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Lundbeck had a recent Job posting/layoffs
Product Launch: Get notified when Lundbeck launches new products
Earning: See what the market has to say on Lundbeck recently announced quarterly report
Check out if Lundbeck is spiking on competitors!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Lundbeck has new funding data
Congratulate Masked Content for being promoted to Masked Content at Lundbeck
Recommended Actions
Reach out to Masked Content who joined Lundbeck as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Lundbeck is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Lundbeck is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Lundbeck.
Lundbeck Tech Stack
A closer look at the technologies used by Lundbeck
See more technologies
Most Recent Scoops
Person-Based
Product Development, Sales
Earnings
continues to expect full-year R&D costs in the range of DKK 5.6 billion to DKK 5.9 billion, reflecting ongoing pipeline investment.
Spending/Investment, Research & Development
Project
Lundbeck has indicated that bexicaserin is progressing toward headline results from two ongoing Phase III trials, with an NDA submission targeted for next year if data readouts are successful.
Clinical Operations
Earnings
Lundbeck has reported adjusted EBITDA growth of 19% at constant exchange rates for H1 2026, primarily driven by strong performance from Vyepti and REXULTI and gross profit benefit from the one-time inventory build, partially offset by higher cost of sales and continued R&D investments.
Earnings, Pharmaceuticals, Finance
Earnings
Earnings, Finance
Lundbeck News & Media
Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in Japan for the prevention of migraine attacks
Approval granted by Japan's Ministry of Health, Labour and Welfare (MHLW) Eptinezumab is the only intravenous (IV) CGRP-targeted preventive treatment approved for the prevention of migraine attacks in adults and launched in over 30 countries worldwide Authorization supported by the Phase...Lundbeck announces last patient randomized in DEEp SEA, a Phase III trial of bexicaserin in Dravet syndrome
DEEp SEA is a global Phase III trial evaluating efficacy, safety and tolerability of the investigational molecule bexicaserin in children and adults with Dravet syndrome1 Completion of randomization marks another important milestone for the global Phase III DEEp program, with...The U.S. FDA grants orphan drug designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for treatment of endogenous Cushing's syndrome
The U.S. FDA has granted Orphan Drug Designation for asedebart (Lu AG13909), Lundbeck's novel investigational anti-ACTH monoclonal antibody, for the treatment of endogenous Cushing's syndrome Endogenous Cushing's Syndrome is a rare endocrine disorder driven in most cases by excess...The U.S. FDA grants orphan drug designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for treatment of endogenous Cushing's syndrome
The U.S. FDA has granted Orphan Drug Designation for asedebart (Lu AG13909), Lundbeck's novel investigational anti-ACTH monoclonal antibody, for the treatment of endogenous Cushing's syndrome Endogenous Cushing's Syndrome is a rare endocrine disorder driven in most cases by excess...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Lundbeck
Sign Up For FreeTo access detailed company insights
Lundbeck, founded in 1915 and headquartered in Valby Denmark, is an international pharmaceutical company that researches, manufactures, and sells drugs for the treatment of psychiatric and neurological disorders.... Read More
